JP2008502738A - ヒトの癌を処置するための、ｖｅｇｆインヒビターの使用 - Google Patents

ヒトの癌を処置するための、ｖｅｇｆインヒビターの使用 Download PDF

Info

Publication number
JP2008502738A
JP2008502738A JP2007527795A JP2007527795A JP2008502738A JP 2008502738 A JP2008502738 A JP 2008502738A JP 2007527795 A JP2007527795 A JP 2007527795A JP 2007527795 A JP2007527795 A JP 2007527795A JP 2008502738 A JP2008502738 A JP 2008502738A
Authority
JP
Japan
Prior art keywords
cancer
vegf
dose
initial dose
flt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007527795A
Other languages
English (en)
Japanese (ja)
Inventor
ジェシー エム． セダーバウム，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2008502738A publication Critical patent/JP2008502738A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2007527795A 2004-06-10 2005-06-10 ヒトの癌を処置するための、ｖｅｇｆインヒビターの使用 Withdrawn JP2008502738A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57849904P 2004-06-10 2004-06-10
PCT/US2005/020762 WO2005123104A2 (en) 2004-06-10 2005-06-10 Use of vegf inhibitors for the treatment of human cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011246211A Division JP2012067116A (ja) 2004-06-10 2011-11-10 ヒトの癌を処置するための、ｖｅｇｆインヒビターの使用

Publications (1)

Publication Number Publication Date
JP2008502738A true JP2008502738A (ja) 2008-01-31

Family

ID=35510259

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007527795A Withdrawn JP2008502738A (ja) 2004-06-10 2005-06-10 ヒトの癌を処置するための、ｖｅｇｆインヒビターの使用
JP2011246211A Withdrawn JP2012067116A (ja) 2004-06-10 2011-11-10 ヒトの癌を処置するための、ｖｅｇｆインヒビターの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011246211A Withdrawn JP2012067116A (ja) 2004-06-10 2011-11-10 ヒトの癌を処置するための、ｖｅｇｆインヒビターの使用

Country Status (9)

Country Link
US (7) US7354580B2 (enExample)
EP (2) EP2583685A1 (enExample)
JP (2) JP2008502738A (enExample)
CN (1) CN101102786A (enExample)
AU (1) AU2005254058A1 (enExample)
CA (1) CA2567686A1 (enExample)
IL (1) IL179515A0 (enExample)
MX (1) MXPA06014421A (enExample)
WO (1) WO2005123104A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013538337A (ja) * 2010-07-19 2013-10-10 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 膵臓癌の治療のためのベバシズマブ組合せ療法のための血漿バイオマーカー
US9657084B2 (en) 2014-01-25 2017-05-23 Chengdu Kanghong Biotechnologies Co., Ltd. Fusion protein inhibiting angiogenesis or growth and use thereof

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1755645A2 (en) * 2004-06-18 2007-02-28 Regeneron Pharmaceuticals, Inc. Vegf inhibitors for the treatment of malignant pleural effusion
CA3142945A1 (en) * 2005-03-25 2006-10-05 Regeneron Pharmaceuticals, Inc. Histidine-buffered formulations of vegf antagonist
AU2006279658A1 (en) * 2005-08-12 2007-02-22 Regeneron Pharmaceuticals, Inc. Treatment of diseases by subcutaneous administration of a VEGF antagonist
US8093259B2 (en) * 2006-05-25 2012-01-10 Novartis Ag 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]-benzamide for treatment of melanoma
CA2654510C (en) 2006-06-16 2015-03-17 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration
GB0612721D0 (en) * 2006-06-27 2006-08-09 Novartis Ag Organic compounds
HRP20160082T1 (hr) 2006-09-29 2016-02-26 Oncomed Pharmaceuticals, Inc. Sastavi i postupci za dijagnosticiranje i lijeäśenje raka
AU2014201795B2 (en) * 2006-12-19 2016-05-19 Genentech, Inc. VEGF-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
US20080248033A1 (en) * 2006-12-19 2008-10-09 Genentech, Inc. VEGF-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
TWI468417B (zh) 2007-11-30 2015-01-11 Genentech Inc 抗－ｖｅｇｆ抗體
CA2746120A1 (en) * 2008-12-23 2010-07-01 Genentech, Inc. Methods and compositions for diagnostic use in cancer patients
HUE052510T2 (hu) 2009-05-27 2021-05-28 Ptc Therapeutics Inc Módszerek a rák és a nem daganatos állapotok kezelésére
EP3485908B1 (en) 2009-10-16 2021-08-18 Mereo BioPharma 5, Inc. Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
KR20180023015A (ko) 2011-01-13 2018-03-06 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
EP2546268A1 (en) 2011-07-13 2013-01-16 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Internalising immunoglobulin
TWI583699B (zh) 2011-09-23 2017-05-21 安可美德藥物股份有限公司 Ｖｅｇｆ／ｄｌｌ４結合劑類及彼等之用途
CA2889638A1 (en) 2012-10-31 2014-05-08 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a dll4 antagonist
MY170528A (en) 2013-02-18 2019-08-09 Vegenics Pty Ltd Vegfr-3 ligand binding molecules and uses thereof
CN104004058B (zh) * 2014-06-23 2016-06-08 栾晓鹏 有关白介素-33抑制剂多肽及其应用
WO2015200905A2 (en) 2014-06-28 2015-12-30 Oligasis, Llc Dual pdgf/vegf antagonists
RS58957B1 (sr) 2014-07-18 2019-08-30 Sanofi Sa Postupak za predviđanje ishoda tretmana sa afliberceptom kod pacijenta za kog se sumnja da boluje od raka
EP3212233B1 (en) 2014-10-31 2020-06-24 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
HK1242996A1 (zh) * 2014-11-14 2018-07-06 豪夫迈．罗氏有限公司 预测对vegf拮抗剂的响应
US11339213B2 (en) 2015-09-23 2022-05-24 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer
IL290457B2 (en) 2015-12-30 2025-02-01 Kodiak Sciences Inc Antibodies and their conjugates
AU2017211247B2 (en) * 2016-01-25 2023-03-09 Sanofi Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer by measuring the level of a plasma biomarker
US10947537B2 (en) * 2016-02-18 2021-03-16 University Of Massachusetts Method of treating VEGF/VEGFR resistant prostate cancer by combining the therapy with RAC1 inhibitors
KR101685532B1 (ko) * 2016-04-26 2016-12-13 한국프라임제약주식회사 혈관내피성장인자 수용체 융합단백질
SG11201908998XA (en) * 2017-03-30 2019-10-30 Progastrine Et Cancers S A R L Compositions and methods for detecting and treating prostate cancer using progastrin binding molecule
US11458126B2 (en) 2017-08-01 2022-10-04 Ptc Therapeutics, Inc. DHODH inhibitor for use in treating hematologic cancers
WO2019083172A1 (ko) * 2017-10-24 2019-05-02 국립암센터 스트렙토니그린 및 라파마이신을 유효성분으로 포함하는, 암 예방 또는 치료용 약학적 조성물
KR20200093621A (ko) 2017-11-30 2020-08-05 리제너론 파아마슈티컬스, 인크. 혈관형성 눈 장애를 치료하기 위한 vegf 길항제의 용도
US11524053B2 (en) 2018-01-26 2022-12-13 The Regents Of The University Of California Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents
CA3092588A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
WO2020106050A1 (ko) * 2018-11-20 2020-05-28 (주)엠디바이오랩 스트렙토니그린 및 항암제를 모두 포함하는 암 예방 또는 치료에 사용하기 위한 약학적 조성물
WO2020159203A1 (ko) * 2019-01-29 2020-08-06 (주)엠디바이오랩 스트렙토니그린 및 항암제를 포함하는 뇌종양 예방 또는 치료용 조성물
WO2020159171A2 (ko) * 2019-02-01 2020-08-06 (주)엠디바이오랩 스트렙토니그린 및 항암제를 포함하는 대장암 예방 또는 치료용 약학적 조성물
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CN114867487A (zh) 2019-11-25 2022-08-05 加利福尼亚大学董事会 用于眼内新生血管的长效vegf抑制剂
MX2022013812A (es) 2020-05-08 2022-12-15 Regeneron Pharma Trampas y mini-trampas de vegf y metodos para el tratamiento de trastornos oculares y cancer.
US20220196166A1 (en) * 2020-12-18 2022-06-23 Nibco Inc. L-ball union drain valve
US11898643B1 (en) 2022-12-28 2024-02-13 Nibco Inc. Dual union ball drain valve with T-flow adjustability
US12140236B2 (en) 2023-02-08 2024-11-12 Nibco Inc. Dual union drain valve with reversible check inserts

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000075319A1 (en) * 1999-06-08 2000-12-14 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US7264801B2 (en) * 1998-08-11 2007-09-04 Genentech, Inc. EG-VEGF nucleic acids and polypeptides and method of use
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US6833349B2 (en) * 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
AU2004242586C1 (en) * 2003-05-28 2011-02-24 Regeneron Pharmaceuticals, Inc. Method of treating corneal transplant rejection by using VEGF antagonists
US7186699B2 (en) 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
CA2519875C (en) * 2003-06-06 2014-01-14 Regeneron Pharmaceuticals, Inc. Method of tumor regression with vegf inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000075319A1 (en) * 1999-06-08 2000-12-14 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN5007014594, ＧＬＡＤＥ−ＢＥＮＤＥＲ ＪＵＬＩＡ， ｅｔ ａｌ．, ＥＸＰＥＲＴ ＯＰＩＮＩＯＮ ＯＮ ＢＩＯＬＯＧＩＣＡＬ ＴＨＥＲＡＰＹ．, 200304, Ｖｏｌ．３ Ｎｏ．２, ｐｐ．２６３−２７６ *
JPN5007014595, ＨＯＬＡＳＨ Ｊ． ｅｔ ａｌ, ＰＮＡＳ, 20020820, Ｖｏｌ．９９ Ｎｏ．１７, ｐｐ．１１３９３−１１３９８, US, ＮＡＴＩＯＮＡＬ ＡＣＡＤＥＭＹ ＯＦ ＳＣＩＥＮＣＥ *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013538337A (ja) * 2010-07-19 2013-10-10 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 膵臓癌の治療のためのベバシズマブ組合せ療法のための血漿バイオマーカー
US9657084B2 (en) 2014-01-25 2017-05-23 Chengdu Kanghong Biotechnologies Co., Ltd. Fusion protein inhibiting angiogenesis or growth and use thereof
KR101789501B1 (ko) * 2014-01-25 2017-10-26 쳉두 캉홍 바이오테크놀로지스 코. 리미티드 혈관의 신생 또는 성장을 억제하는 융합 단백질 및 그 용도

Also Published As

Publication number Publication date
US20080214465A1 (en) 2008-09-04
US7482001B2 (en) 2009-01-27
US20080171703A1 (en) 2008-07-17
US7482002B2 (en) 2009-01-27
US20050276808A1 (en) 2005-12-15
US7479273B2 (en) 2009-01-20
US20080188419A1 (en) 2008-08-07
MXPA06014421A (es) 2007-05-04
US20080214466A1 (en) 2008-09-04
JP2012067116A (ja) 2012-04-05
US7479272B2 (en) 2009-01-20
CA2567686A1 (en) 2005-12-29
CN101102786A (zh) 2008-01-09
US20080188420A1 (en) 2008-08-07
US7354580B2 (en) 2008-04-08
AU2005254058A1 (en) 2005-12-29
EP1753442A2 (en) 2007-02-21
IL179515A0 (en) 2007-05-15
EP2583685A1 (en) 2013-04-24
US7479275B2 (en) 2009-01-20
WO2005123104A2 (en) 2005-12-29
WO2005123104A3 (en) 2006-04-27
US20080188418A1 (en) 2008-08-07
US7479274B2 (en) 2009-01-20

Similar Documents

Publication Publication Date Title
JP2012067116A (ja) ヒトの癌を処置するための、ｖｅｇｆインヒビターの使用
RU2571220C2 (ru) Способ лечения рака антагонистом dll4 и химиотерапевтическим средством
JP5737826B2 (ja) Ｖｅｇｆの阻害による貧血の処置
KR20250159733A (ko) Psgl-1 길항제 및 그의 용도
KR20160048095A (ko) 교모세포종을 치료하기 위한 병용 요법
CN105214086A (zh) 抗-vegf抗体与化学治疗联合用于治疗乳腺癌的应用
JP6371294B2 (ja) Ｄｌｌ４アンタゴニストによる処置の方法およびモニタリング
US20230227823A1 (en) Fmrp and cancer treatment
ES2874668T3 (es) Conjugados anticuerpo-fármaco dirigidos a uPARAP
US7354582B2 (en) Use of VEGF antagonists for the treatment of malignant gliomas
CN102573909A (zh) 抗血管发生疗法用于治疗先前治疗过的乳腺癌
WO2025250689A1 (en) Combination therapy with angiogenesis protein and immune checkpoint inhibitor with/without chemotherapeutics

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101124

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110121

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110519

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110711

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111110

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20111212